Company Overview and News

 
South Crofty Operations Update

2018-10-09 globenewswire
VANCOUVER, British Columbia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Strongbow Exploration Inc. (TSX-V: SBW) (“Strongbow” or the “Company”) is pleased to provide the following operational update regarding the South Crofty tin project, Cornwall, UK.
BBYB OKSWF BBY OR SU OSKGF BAFYY SBWFF BAFBF

1
Resource Sector Digest: Homework On Osisko Gold Royalties

2018-10-08 seekingalpha
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
WOPEF LBGO BLT PVG IVN SMNPF TREVF BTG OR FQVLF USAPF CCJ FQM LGDTF DNN OKSWF BHPBF URG DML USAS WPL WOPEY IVPAF PVG BHP BBL BHP OSKGF BHPLF PGLC FNV

1
OR / Osisko Gold Royalties Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-10-02 sec.gov - 1
Osisko Gold Royalties Ltd. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2018 Commission File Number: 0
OR

 
Stornoway Announces Comprehensive Financing Agreements Valued at Up To $129 M

2018-10-02 globenewswire
LONGUEUIL, Quebec, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Stornoway Diamond Corporation (TSX-SWY; the “Corporation” or “Stornoway”) is pleased to announce the entering into a series of financing transactions with lenders and key stakeholders designed to provide the Corporation greater financial and operational flexibility (the “Financing Package”). In total, the Financing Package represents additional consideration and liquidity for the Corporation of up to $129 million by way of:
SWYDF OKSWF OR MALRY OSKGF MALRF SWY MIN

 
Osisko Enters Into Agreement to Amend Renard Stream

2018-10-02 globenewswire
MONTREAL, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (“Osisko”) (OR: TSX & NYSE) is pleased to announce that it has entered into an amended and restated purchase and sale agreement (the “Amended Renard Streaming Agreement”) with Stornoway Diamond Corporation (“Stornoway”) in relation to the Renard Stream (as herein defined) (“Stream Amendment”). As part of the Stream Amendment, Osisko will provide Stornoway with the US$ equivalent of C$21.
SWYDF FPC OKSWF OR OR OSKGF BGMZF FPRGF VITFF SWY VIT

1
OR / Osisko Gold Royalties Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-09-25 sec.gov - 1
Osisko Gold Royalties Ltd. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number:
OR

33
Resource Sector Digest: New Gold Cleaning The Slate, Again

2018-09-25 seekingalpha - 1
Another CEO is having a shot at fixing New Gold. Unfortunately, things have gone from bad to worse since the last iteration on this theme. Welcome to this week's
OCANF CAT IVN LIACF TMMFF NGD NSU BTR AMGGF IAG IPMLF ABX III NGD GPL OKSWF EQXGF RGLD ATUSF MNIKF AMLM OSKGF VTT RGL HRT VDTAF HRTFF BDREF CGOOF KGI.DB NGDAF CG VITFF TREVF AGI CAGDF OR RIC CSFFF CS KL CORVF EGO RIC ABX KOR KGI KGI.DB.A AGI BDR VIT IVPAF TMR ELD

 
Pretium Resources Is Getting Its Ducks In A Row

2018-09-25 seekingalpha
Some proposals to refinance the company's credit facility by the end of 2018 are being evaluated.
PVG OKSWF OR PVG OSKGF

4
Osisko Gold Royalties: Second Quarter Results Analysis

2018-09-24 seekingalpha
Osisko Gold Royalties posted a revenue of US$106.75 million in the second quarter 2018, up 7.3% sequentially.
WPM SAND SSL SDDXF OKSWF BGMZF SNXZF RGLD FPC OR OSKGF FPRGF FNV RGL

 
Victoria Gold Receives C$87.2 Million in Cash from Funding Partners

2018-09-24 globenewswire
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Victoria Gold Corp. (TSX.V-VIT) “Victoria” or the “Company” is pleased to announce that it has received cash as per its financing facilities (See press release “Victoria Gold Announces Comprehensive C$500 Million Financing Package for Eagle and Continuation of Construction Activities” dated March 8, 2018).
OKSWF OR OSKGF VITFF VIT

2
The Right Price: Are Pretium Resources And Detour Gold For Sale?

2018-09-21 seekingalpha
Gold market sentiment is at historic sentiment lows - here's what it means in the coming months.
PVG KGI AUY DGC KGI.DB.A KGI.DB OR PVG AEM DRGDF KL

 
OR / Osisko Gold Royalties Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-09-19 sec.gov
Osisko Gold Royalties Ltd. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number:
OR

8
Zacks.com featured highlights include: First Majestic, Agnico Eagle, AMC and Osisko

2018-09-14 zacks
Chicago, IL – September 14, 2018 - Stocks in this week’s article are First Majestic Silver Corp. (AG - Free Report) , Agnico Eagle Mines Ltd. (AEM - Free Report) , AMC Entertainment Holdings, Inc. (AMC - Free Report) and Osisko Gold Royalties Ltd. (OR - Free Report) .
FR STZ.B AMC CY OKSWF OR AEM OSKGF AG STZ

5
Goldcorp: Q2 In A Few Charts

2018-09-14 seekingalpha - 1
We are not big fans of Goldcorp (GG), but we keep updating our spreadsheets on the major in order to see how the 20-20-20 plan is panning out. Here is a snapshot following Q2 results, in just a few charts...
OKSWF OR OSKGF GG

 
OR / Osisko Gold Royalties Ltd. FORM 6-K (Current Report of Foreign Issuer)

2018-09-13 sec.gov
Osisko Gold Royalties Ltd. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2018 Commission File Number:
OR

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to OR / Osisko Gold Royalties Ltd. on message board site Silicon Investor.

Formerly About Advanced Micro Devices Formerly About Advanced Micro Devices Formerly About Advanced Micro Devices Favorite Quotes Favorite Quotes Favorite Quotes
Clown-Free Zone... sorry, no clowns allowed Clown-Free Zone... sorry, no clowns allowed Clown-Free Zone... sorry, no clowns allowed CFZ E-Wiggle Workspace CFZ E-Wiggle Workspace CFZ E-Wiggle Workspace
Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting Qualcomm Moderated Thread - please read rules before posting OLED Universal Display Corp OLED Universal Display Corp OLED Universal Display Corp
The Philosophical Porch The Philosophical Porch The Philosophical Porch World Outlook World Outlook World Outlook
Politics for Conservatives Politics for Conservatives Politics for Conservatives Liberty Star Uranium and Metals Corp. Liberty Star Uranium and Metals Corp. Liberty Star Uranium and Metals Corp.
CUSIP: 68827L952